Repeating the exact same cycle and hoping is not a plan. A structured re-evaluation of embryo, uterus, endometrium, and tubes — before you spend again.
✍️ By Dr. Patsama Vichinsartvichai, MD, MClinEmbryol, EFOG-EBCOG, EFRM-ESHRE/EBCOG, FACOG — Reproductive Medicine Specialist · Updated August 2026
A single failed transfer — even with a good-quality blastocyst — is statistically unremarkable: implantation rates per euploid blastocyst run around 50–65% at best. Many couples simply need cumulative attempts. Repeated implantation failure (RIF) is conventionally considered after roughly three failed transfers of good-quality embryos — that's the point where a systematic second look earns its place.
Implantation requires a chromosomally competent embryo, a normal uterine cavity, a receptive endometrium, and the absence of hostile factors like tubal fluid. A structured re-evaluation walks through exactly these four, in order of likelihood.
Stimulation response, egg maturity, fertilization rate, embryo development day by day, and grading — the previous cycle's records often point to the weak link before any new test.
Embryo aneuploidy is the single biggest reason transfers fail, and it climbs steeply with age. For selected patients, PGT-A testing of the next cohort clarifies whether embryos or the uterus deserve the focus.
Polyps, adhesions, submucous fibroids, chronic endometritis, and dysmorphic (T-shaped) cavities all reduce implantation — and most are invisible on routine 2D scans. We re-examine with 3D-TVUS + SIS and, when indicated, no-touch office hysteroscopy, treating findings in the same setting where possible.
In a minority of patients the implantation window is shifted. Receptivity testing (ERA, or our no-biopsy ORA approach) can personalize transfer timing — evidence is mixed as a routine test, so we use it selectively where the pattern fits.
A fluid-filled blocked tube roughly halves implantation rates; treating it before the next transfer is one of the best-proven interventions in IVF. Thyroid status, BMI, smoking, and sperm factors are reviewed alongside.
Failed cycles make patients vulnerable to expensive, unproven add-ons. Immune infusions, routine steroids, and blanket "endometrial scratching" lack convincing evidence of benefit in current trials — our position, with references, is in the IVF add-ons evidence review. Every intervention we recommend after a failed cycle has a diagnosis behind it.
Book a Consultation Virtual Consult from Abroad
Implantation rates are roughly 50–65% per good-quality euploid blastocyst, so one or two failures can be pure chance. After about three failed transfers of good embryos, a systematic re-evaluation of embryo quality, the uterine cavity, receptivity, and tubal factors is justified.
Chromosomal abnormality of the embryo — the probability rises sharply with maternal age. That's why reviewing embryo development records, and in selected cases PGT-A testing, comes first in the re-evaluation.
If 3D ultrasound or saline sonography suggests any cavity abnormality — polyp, adhesions, septum, T-shaped cavity, or suspected chronic endometritis — yes. Office hysteroscopy confirms and usually treats the finding in one sitting.
Selectively. A displaced implantation window affects a minority of patients, and routine ERA for everyone hasn't shown clear benefit in trials. It's most reasonable after repeated failures of good-quality (especially euploid) embryos with a normal cavity.
Current evidence does not support routine immune testing or treatments such as intralipid infusions or IVIG for implantation failure. We follow the evidence and explain it openly rather than adding costly, unproven extras.
Dr. Patsama Vichinsartvichai, MD, MClinEmbryol, EFOG-EBCOG, EFRM-ESHRE/EBCOG, FACOG is a board-certified reproductive endocrinology & infertility specialist, former head of the Vajira IVF unit at Navamindradhiraj University, and founder of LIFE by Dr. Pat in Bangkok. His published research focuses on the dysmorphic (T-shaped) uterus and uterine-factor infertility.
Meet Dr. Patsama →